X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9) 9
aged (7) 7
cancer (7) 7
female (7) 7
hematology, oncology and palliative medicine (7) 7
humans (7) 7
male (7) 7
middle aged (7) 7
oncology (7) 7
care and treatment (6) 6
chemotherapy (6) 6
lung cancer (6) 6
lung neoplasms - drug therapy (6) 6
medical colleges (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
carcinoma, non-small-cell lung - drug therapy (5) 5
lung cancer, non-small cell (5) 5
lung neoplasms - pathology (5) 5
neoplasm staging (5) 5
product development (5) 5
adult (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
cisplatin - administration & dosage (4) 4
combination (4) 4
lung neoplasms - genetics (4) 4
lung neoplasms - mortality (4) 4
mutation (4) 4
carcinoma, non-small-cell lung - mortality (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
carcinoma, squamous cell - drug therapy (3) 3
clinical trials (3) 3
clinical-trials (3) 3
college teachers (3) 3
disease-free survival (3) 3
gefitinib (3) 3
iii trial (3) 3
japan (3) 3
kaplan-meier estimate (3) 3
nanoparticles (3) 3
pharmaceutical industry (3) 3
prognosis (3) 3
quinazolines - administration & dosage (3) 3
receptor, epidermal growth factor - genetics (3) 3
respiratory agents (3) 3
treatment outcome (3) 3
analysis (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bevacizumab (2) 2
camptothecin - administration & dosage (2) 2
camptothecin - analogs & derivatives (2) 2
cancer therapies (2) 2
carcinoma, squamous cell - genetics (2) 2
carcinoma, squamous cell - mortality (2) 2
carcinoma, squamous cell - pathology (2) 2
chemistry, physical (2) 2
disease (2) 2
disease progression (2) 2
drug administration schedule (2) 2
efficacy (2) 2
erlotinib (2) 2
etoposide (2) 2
etoposide - administration & dosage (2) 2
etoposide/cisplatin (2) 2
follow-up studies (2) 2
gemcitabine (2) 2
gene (2) 2
gene deletion (2) 2
kinases (2) 2
maximum tolerated dose (2) 2
multicenter (2) 2
neutropenia (2) 2
pharmaceuticals (2) 2
placebo (2) 2
proportional hazards models (2) 2
recruitment (2) 2
survival (2) 2
time factors (2) 2
toxicity (2) 2
1st-line therapy (1) 1
abridged index medicus (1) 1
abstracts (1) 1
acquired-resistance (1) 1
activation (1) 1
adenocarcinoma (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - genetics (1) 1
adenocarcinoma - metabolism (1) 1
administration, oral (1) 1
advanced nsclc (1) 1
af-001jp (1) 1
afatinib (1) 1
alpha (1) 1
anaplastic lymphoma (1) 1
anaplastic lymphoma kinase (1) 1
animals (1) 1
antibodies, monoclonal, humanized - administration & dosage (1) 1
antigens (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - administration & dosage (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed... 
Hematology, Oncology and Palliative Medicine | FUSION | GENE | ONCOLOGY | C-MET | KINASE | CRIZOTINIB | ANAPLASTIC LYMPHOMA | INHIBITOR | ROS1 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1236 - 1244
Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer... 
Hematology, Oncology and Palliative Medicine | TRIAL | GROWTH-FACTOR RECEPTOR | CISPLATIN PLUS GEMCITABINE | GEFITINIB | PLACEBO | EFFICACY | NSCLC | ONCOLOGY | DOUBLE-BLIND | COMBINATION | CHEMOTHERAPY | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Confidence Intervals | Prognosis | Lung Neoplasms - mortality | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Receptor, Epidermal Growth Factor - drug effects | Lung Neoplasms - pathology | Male | Bevacizumab | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Squamous Cell - mortality | Neoplasm Invasiveness - pathology | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Neoplasm Staging | Development and progression | Care and treatment | Cross infection | Nosocomial infections | Erlotinib | Lung cancer, Non-small cell | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1630 - 1638
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1147 - 1157
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 1, pp. 106 - 113
Journal Article
Journal of Physical Chemistry C, ISSN 1932-7447, 07/2009, Volume 113, Issue 30, pp. 13450 - 13455
A valence state and a local structure of transition metals (Nb, V, and Ti) in MgH2 doped with metal oxides (Nb2O5, V2O5, and TiO2nano) by ball milling were... 
HYDROGEN SORPTION PROPERTIES | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | H-SORPTION | NB2O5 | MAGNESIUM | NANOPARTICLES | STORAGE PROPERTIES | NANOCRYSTALLINE MG | KINETICS | MG+CR2O3 MIXTURES | NI NANO-PARTICLE
Journal Article
ISSN 0264-410X, 03/2008, Volume 26, Issue 10, p. 1303
  Nanotechnology is a fundamental technology for designing and generating innovative carriers for biomacromolecular drugs. Biodegradable poly(γ-glutamic... 
Proteins | Nanoparticles | Antigens | Lymphocytes | Efficiency | Immunotherapy | T cell receptors | Immune system | Cancer
Journal Article
Digestion, ISSN 0012-2823, 01/2012, Volume 85, Issue 2, pp. 143 - 176
Journal Article
Oncogene, ISSN 0950-9232, 03/2003, Volume 22, Issue 11, pp. 1653 - 1662
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily, induces apoptosis in a variety of cancer cells with... 
Journal Article
Journal of Photochemistry & Photobiology, A: Chemistry, ISSN 1010-6030, 2011, Volume 223, Issue 2, pp. 119 - 123
► Ultrafast photoisomerization and relaxation dynamics of 4′-methylthioazobenzene binding to DNAs and azobenzene were investigated by the measurement of fs... 
Intramolecular electron transfer |